Nasus Pharma appoints Nir Sassi as chief financial officer
NSRX•Nasus Pharma appointed Nir Sassi chief financial officer, effective November 11, 2026.
NSRX•Nasus Pharma appointed Nir Sassi chief financial officer, effective November 11, 2026.
Sassi most recently served as CFO of Indaptus Therapeutics and previously held the same role at Intec Pharma. He brings nearly 25 years of experience in public company finance, capital markets and biopharmaceutical operations.